HER2-Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0.

Breast J · 2026 · PMC13291886 · PMID 42340017

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significancep − value > 0.05actually significant

While we observed shorter median TTFs after all LOTs for the HER2‐ultralow HR+ cohort compared to the no observable staining HR+ cohort, these differences did not reach statistical significance by log‐rank testing regardless of the LOT number (across LOT p − value > 0.05). 4.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.